Pioneer the future of Cell Avidity measurement

Avidion Early Access is a tailored scientific partnership for a limited group of teams, who want to apply Avidion’s Cell Avidity measurements in drug development workflows, while also helping shape the platform future developments throughstructured feedback and collaboration with our scientific and product teams.

This program is ideal for labs and organizations working in cell therapy discovery and development (e.g., CAR‑T, TCR‑T, NK) or cell engager development, who want to accelerate lead selection and characterization using quantitative Cell Avidity insights, and who are excited to collaborate closely with LUMICKS.

As an Early Access partner, you’re among the very first teams worldwide to access the Avidion for preclinical and drug‑development programs. This enables you to generate Cell Avidity datasets earlier, accelerate internal learning, and integrate new insights directly into active research decisions. Early users leverage this head start to inform candidate selection, improve pipeline strategy, and shape downstream studies well before these capabilities become widely available in the field.

Early Access partners receive dedicated Application Scientist support and structured touchpoints to ensure project success, plus collaboration on experimental design, best practices, and data analysis so your assays are optimized for your goals.

Your experiments and feedback directly inform future Avidion improvements, including workflow refinements and ongoing hardware/software evolution, through collaboration with our product and scientific teams.

Yes. Avidion Early Access is designed for teams who want to secure early placement of Avidion for their lab/organization. If you’re interested, submit the form and we’ll discuss fit, timing, and the pathway to secure an Early Access slot.

Avidion is designed for automated, high-throughput cell avidity measurements with 96-well plate compatibility and 4-color fluorescence readouts. It can run up to four 48-well cartridges per day (up to 192measurements/day) with low hands-on time through automated handling and analysis.

Yes. If your application involves cell-cell or cell-protein binding questions where quantitative avidity insights could help, submit the form and tell us what you’re trying to measure. We’ll schedule a discussion to assess feasibility and fit.